Resolution of a Refractory Anastomotic Stricture With a Novel Biodegradable Esophageal Stent

Muñoz, Diego Sánchez; Ortiz–Moyano, Carlos; Gomez-Rodriguez, Blas J.

doi:10.1016/j.cgh.2012.11.023

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ELLa-BDS is recognized as the first commercially available biodegradable esophageal stent ( Vandenplas et al, 2009 ; Repici et al, 2010 ; Stivaros et al, 2010 ) and has been extensively employed in clinical studies to evaluate its effectiveness and safety in the treatment of BES ( Table 3 ). Previous studies have shown that ELLa-BDS offers a practical approach to managing RBES by reducing the need for repetitive endoscopic dilations and cutting treatment costs ( Dhar et al, 2009 ; Repici et al, 2010 ; van Boeckel et al, 2011 ; Muñoz et al, 2013 ). A single BDS placement provides only temporary relief; therefore, the sequential placement of stents emerges as an excellent option to preclude the need for serial dilations ( Hirdes et al, 2012a ).…”

Section: Materials Used In Biodegradable Esophageal Stentsmentioning

confidence: 99%

Comprehensive review of materials, applications, and future innovations in biodegradable esophageal stents

Yang,

Hou

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Esophageal stricture (ES) results from benign and malignant conditions, such as uncontrolled gastroesophageal reflux disease (GERD) and esophageal neoplasms. Upper gastrointestinal endoscopy is the preferred diagnostic approach for ES and its underlying causes. Stent insertion using an endoscope is a prevalent method for alleviating or treating ES. Nevertheless, the widely used self-expandable metal stents (SEMS) and self-expandable plastic stents (SEPS) can result in complications such as migration and restenosis. Furthermore, they necessitate secondary extraction in cases of benign esophageal stricture (BES), rendering them unsatisfactory for clinical requirements. Over the past 3 decades, significant attention has been devoted to biodegradable materials, including synthetic polyester polymers and magnesium-based alloys, owing to their exceptional biocompatibility and biodegradability while addressing the challenges associated with recurring procedures after BES resolves. Novel esophageal stents have been developed and are undergoing experimental and clinical trials. Drug-eluting stents (DES) with drug-loading and drug-releasing capabilities are currently a research focal point, offering more efficient and precise ES treatments. Functional innovations have been investigated to optimize stent performance, including unidirectional drug-release and anti-migration features. Emerging manufacturing technologies such as three-dimensional (3D) printing and new biodegradable materials such as hydrogels have also contributed to the innovation of esophageal stents. The ultimate objective of the research and development of these materials is their clinical application in the treatment of ES and other benign conditions and the palliative treatment of malignant esophageal stricture (MES). This review aimed to offer a comprehensive overview of current biodegradable esophageal stent materials and their applications, highlight current research limitations and innovations, and offer insights into future development priorities and directions.

show abstract

Section: Materials Used In Biodegradable Esophageal Stentsmentioning

confidence: 99%

Comprehensive review of materials, applications, and future innovations in biodegradable esophageal stents

Yang,

Hou

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…The degradation process is accelerated by a low pH and acid-suppressing therapy (proton-pump inhibitors) is recommended to prolong stent integrity. A limited number of cohort studies have been reported with the ELLA-BDS for management of benign esophageal diseases such as benign esophageal strictures (BES), refractory benign esophageal stricture (RBES) [3,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75] (Figure 6) and achalasia [61] (Table 1). Technical success, clinical responses and outcomes were different.…”

Section: Clinical Studies With Biodegradable Esophageal Stentsmentioning

confidence: 99%

Polymeric Biodegradable Stent Insertion in the Esophagus

et al. 2016

View full text Add to dashboard Cite

Esophageal stent insertion has been used as a well-accepted and effective alternative to manage and improve the quality of life for patients diagnosed with esophageal diseases and disorders. Current stents are either permanent or temporary and are fabricated from either metal or plastic. The partially covered self-expanding metal stent (SEMS) has a firm anchoring effect and prevent stent migration, however, the hyperplastic tissue reaction cause stent restenosis and make it difficult to remove. A fully covered SEMS and self-expanding plastic stent (SEPS) reduced reactive hyperplasia but has a high migration rate. The main advantage that polymeric biodegradable stents (BDSs) have over metal or plastic stents is that removal is not require and reduce the need for repeated stent insertion. But the slightly lower radial force of BDS may be its main shortcoming and a post-implant problem. Thus, strengthening support of BDS is a content of the research in the future. BDSs are often temporarily effective in esophageal stricture to relieve dysphagia. In the future, it can be expect that biodegradable drug-eluting stents (DES) will be available to treat benign esophageal stricture, perforations or leaks with additional use as palliative modalities for treating malignant esophageal stricture, as the bridge to surgery or to maintain luminal patency during neoadjuvant chemoradiation.

show abstract